Tirzepatide and Mounjaro: What the Names Mean

Tirzepatide is the name of an active substance. Mounjaro is the name of a finished medicine that contains it. The two names are connected, but they answer different questions: “Which molecule?” and “Which product?” The EMA medicine record identifies tirzepatide as Mounjaro’s active substance.

This distinction matters when a search shows a Mounjaro carton beside an independently supplied pen described simply as tirzepatide. The shared ingredient name helps identify the intended molecule; it does not identify the manufacturer, formulation or device.

Read the name at three levels

Start with the active substance. Tirzepatide acts at GIP and GLP-1 receptors, which explains the dual-receptor description in its medicine information. Those abbreviations describe biological targets, not two separate ingredients mixed in the pen. EMA overview.

Next comes the finished product. A product name connects the substance to a particular formulation, presentation and responsible company. Finally, the pack description identifies the exact presentation you are looking at. The Mounjaro product information distinguishes presentations and their corresponding labeling; a photograph of one format cannot stand in for every other format.

What a 30 mg or 60 mg listing adds

The Bodypharm catalog lists tirzepatide variants with declared contents of 30 mg or 60 mg per pen. The amount alone does not show that either pen is a Mounjaro presentation.

Nor does the larger number tell you the amount delivered in one administration. Total content, concentration and the device’s specified output describe different things. A comparison that matches only the word tirzepatide and the largest number can therefore pair unlike products.

Three descriptions side by side

These descriptions operate at different levels. A comparison of Mounjaro with a catalog pen is a comparison of finished products containing the same named ingredient; the shared name alone does not make their product identities identical.